Comparing Evolva (OTCMKTS:ELVAF) & Adial Pharmaceuticals (NASDAQ:ADIL)

Evolva (OTCMKTS:ELVAF) and Adial Pharmaceuticals (NASDAQ:ADIL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.

Insider and Institutional Ownership

22.0% of Evolva shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 1.9% of Adial Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Evolva and Adial Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evolva	N/A	N/A	N/A
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Evolva and Adial Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolva	0	0	0	0	0.00
Adial Pharmaceuticals	1	1	1	0	2.00

Adial Pharmaceuticals has a consensus price target of $22.75, indicating a potential upside of 1,548.55%. Given Adial Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Evolva.

Valuation and Earnings

This table compares Evolva and Adial Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolva	N/A	N/A	N/A	C($0.08)	-14.13
Adial Pharmaceuticals	N/A	N/A	-$7.98 million	($15.00)	-0.09

Evolva is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Adial Pharmaceuticals beats Evolva on 5 of the 9 factors compared between the two stocks.

About Evolva

Evolva Holding SA is in the process of liquidation of its remaining assets. Previously, the company was engaged in discovery, research, development, and commercialization of nature-based ingredients for use in flavor and fragrances, health ingredients, health protection, and other sectors in Switzerland, the United States, and internationally. The company was founded in 2004 and is headquartered in Reinach, Switzerland.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.